Last reviewed · How we verify
LDAC and/or Mitoxantrone
LDAC (low-dose cytarabine) and mitoxantrone are chemotherapy agents that inhibit DNA synthesis and topoisomerase II, respectively, to kill rapidly dividing leukemic cells.
LDAC (low-dose cytarabine) and mitoxantrone are chemotherapy agents that inhibit DNA synthesis and topoisomerase II, respectively, to kill rapidly dividing leukemic cells. Used for Acute myeloid leukemia (AML), particularly in elderly or unfit patients, Relapsed or refractory acute leukemia.
At a glance
| Generic name | LDAC and/or Mitoxantrone |
|---|---|
| Sponsor | DKMS gemeinnützige GmbH |
| Drug class | Chemotherapy combination (nucleoside analog + topoisomerase II inhibitor) |
| Target | DNA polymerase (cytarabine); Topoisomerase II (mitoxantrone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Low-dose cytarabine is a nucleoside analog that incorporates into DNA and inhibits DNA polymerase, while mitoxantrone is a topoisomerase II inhibitor that causes DNA strand breaks. Together, they are used in combination chemotherapy regimens to treat acute myeloid leukemia and other hematologic malignancies by inducing apoptosis in leukemic blasts.
Approved indications
- Acute myeloid leukemia (AML), particularly in elderly or unfit patients
- Relapsed or refractory acute leukemia
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Mucositis
- Nausea and vomiting
- Cardiotoxicity (mitoxantrone-related)
- Hepatotoxicity
Key clinical trials
- Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia (PHASE3)
- Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs (PHASE3)
- Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML (PHASE3)
- Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LDAC and/or Mitoxantrone CI brief — competitive landscape report
- LDAC and/or Mitoxantrone updates RSS · CI watch RSS
- DKMS gemeinnützige GmbH portfolio CI